… ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate … Ionis Pharmaceuticals ProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx , now QR-1123, for autosomal … the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly “IONIS-RHO-2.5 Rx ”), an RNA …
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Companies … N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and …
… assets. ProQR continues to execute on its global licensing and research partnership with Eli Lilly, focused on … Carreño was most recently Global Business Development & Licensing Head (BD&L) in the Ophthalmology franchise at …
… Carreño was most recently Global Business Development & Licensing Head (BD&L) in the Ophthalmology franchise at … franchises, as well as a proven track record in licensing deals and M&A. Before joining Novartis, she was the …
… targets identified by Galapagos -- ProQR plans additional licensing, partnering and other strategic relationships for … and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated …
… Eli Lilly and Company (Lilly) and ProQR entered into a licensing and research collaboration related to ProQR’s … payment of $20 million from Lilly related to the Axiomer licensing and research collaboration. Research and …
… these ProQR-owned patents, the Company has an exclusive license to U.S. patent no. 9,617,535 from Massachusetts … and create value for this novel technology through licensing, partnering and other strategic relationships. In …
